Feb 18, 2020: The global inflammatory bowel disease treatment market size is expected to reach USD 22.4 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.4% CAGR during the forecast period. Increasing prevalence and incidence of Crohn's disease and ulcerative colitis is one of the major factors contributing to the market.
According to a study published in the NCBI in 2019, the North America incidence of inflammatory bowel disease (IBD) treatment is around 2.2 to 19.2 cases per 100,000 persons per year. It was also published that around 238 per 100,000 populations in U.S. were suffering from ulcerative colitis. Furthermore, The Centres for Disease Control and Prevention (CDC) estimates that in U.S., every year nearly 1-1.3 million people suffer from inflammatory bowel disease.
Request a Free Sample Copy of Inflammatory Bowel Disease Treatment Market Report @ https://www.radiantinsights.com/research/inflammatory-bowel-disease-treatment-market/request-sample
In addition, involvement of regulatory bodies for funding and designation is expected to propel the growth of the market. For instance, the Crohn's and Colitis Foundation offers grants and fellowships for research on inflammatory bowel disease (includes Crohn's disease and ulcerative colitis).
Growing geriatric population is expected to positively impact the overall market. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, the population aged 65 years and above is expected to reach 78 million, whereas children under the age of 18 might be around 76.7million.
Moreover, companies such as Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; and AbbVie Inc. are majorly involved in product research and development and this is also considered as one of the major driving factors for the market.
For further inquiries, about - Global Inflammatory Bowel Disease Treatment Industry Analysis, Size, Growth, Trends and Forecast 2019 - 2026, click on this link – https://www.radiantinsights.com/research/inflammatory-bowel-disease-treatment-market
Further key findings from the report suggest:
• The global inflammatory bowel disease treatment market is anticipated to reach USD 22.4 billion by 2026, exhibiting a CAGR of 4.4% from 2018 to 2026
• Crohn's disease dominated the market by type in 2018 due to increasing incidence of the disease. On the other hand, ulcerative colitis was estimated to be the fastest growing segment owing to presence of strong pipeline products for its treatment
• By route of administration, injectables dominated the IBD treatment market in 2018 while oral was estimated to be the fastest growing segment over the forecast period
• Aminosalicylic acid (ASAs) was considered to be the largest oral segment in 2018 and JAK inhibitors to be the fastest growing segment
• In 2018, TNF-inhibitors dominated the injectables segment while anti-integrins are estimated to be the fastest growing segment
• Hospital pharmacy was the largest segment in 2018 with a market share of 36.6% and online pharmacy was anticipated to be the fastest owing to the comfort, flexibility and convenience provided
• North America held the dominant share in 2018 owing to presence of key companies in this region. Asia Pacific, on the other hand, was estimated to be the fastest growing region
• Some of the key companies operating in this inflammatory bowel disease treatment market are Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead Sciences.
Jul 19, 2019 (AB Digital via COMTEX) -- Global ePharmacy Market is estimated to experience a sturdy CAGR in the coming years.
With the augmenting proliferation of internet and penetration of smartphone users, the healthcare sector is deploying technologically advanced healthcare solutions.
On the contrary, low penetration of advanced technology, especially in the underdeveloped regions, is considered to deter the ePharmacy market growth throughout the estimated period.
Global ePharmacy Market: Segmental Analysis
The global ePharmacy market has been segmented on the basis of product type and drug type.
On the other hand, Latin America and the Asia Pacific are predicted to emerge at a rapid pace.
The global antiviral drugs market is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art therapeutics.
Fortune Business Insights™ published this information in a recent study, titled, “Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026.” The study further mentions that the antiviral drugs market size is projected to reach USD 44.2 billion by 2026, thereby exhibiting a CAGR of 3.2% during the forecast period.
We understand that this health crisis has brought an unprecedented impact on businesses across industries.
Rising support from governments and several companies can help in the fight against this highly contagious disease.
Overall, almost every sector is anticipated to be impacted by the pandemic.We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics.
The diagnosis rate of HIV is improving gradually owing to the refinement of surveillance by using biological and demographic data.
Overview:Market Research Future (MRFR), in its attempt to understand the market proceedings, has revealed several factors that can impact the growth.
The better technological influx and their easy integration in the mainstream, improvement in the infrastructure, and a rise in investment to boost the research works would help the global market achieve growth.
Request Sample Copy:https://www.marketresearchfuture.com/sample_request/7397The global plasma fractionation market is showing ample scope for growth and it is projected to secure a 6.5% CAGR during the forecast period of 2018 to 2023.Segmentation:The global market for plasma fractionation has been segmented by market researchers on the basis of product, application, and end user.
By product, the global market study on the plasma fractionation has been segmented into coagulation factor concentrates, protease inhibitors, albumin, immunoglobulin, and others.
The immunoglobulin segment has been segmented further into subcutaneous immunoglobulin (SCIG), intravenous immunoglobulin (IVIG), and others.By application, the global discussion on the plasma fractionation market includes neurology, hematology, immunology, hemato-oncology, pulmonology, rheumatology, critical care, and others.
Various clinical research laboratories are impacting the global market as they are trying to develop new methods of treatments.
